A little more information has been added to the session detail - for the end of next weeks abstracts at SNO, in Toronto.
Nothing too exciting - but CEO James Garner is now listed as a presenting study author...together with mostly researchers from Memorial Sloan.
This trial conclusion date has been extended until Dec 2023 and most importantly, is still recruiting.
A week out - surely James Garner, is aware of the key findings in this study. The possibility that our drug may assist radiation work better - is very simple for investors to understand. An undeniable headline grabber, without complexity that comes with most other cancer drug study successes.
Off that tiny cap - and the study release presentation from Memorial Sloan - (paxalisb makes radiation work better) it would be trading and SP strength, of something very special.
If in fact, paxalisib is demonstrated to work in this trial......the disappointment of last Monday would quickly be forgotten.
James knows the answer to next Friday nights release. Maybe just maybe - investors may seek only limited updates on this companies GBM drug development in future......due to the high level implications of this trial result.
Its real here - it could be on like you have never seen before - or maybe NOT.
Phase I study of concurrent paxalisib and radiation therapy in patients with solid tumor brain metastases or leptomeningeal metastases harboring PI3K pathway mutations: results from the dose-escalation cohort
Jonathan Yang1, Justin Mann1, Luke Pike1, Melissa Zinovoy1, Robert Young1, Michael Offin1, Ryan Mitchell1, Arousiak Kazarian1, Tamim Shadat1, James Garner2, Jeremy Simpson2, John Friend2, Igor Gavrilovic1, Anna Piotrowski1, Jessica Wilcox1, Rachna Malani1, Eli Diamond1 1 Memorial Sloan Kettering Cancer Center, New York/NY, USA. 2 Kazia Therapeutics Limited, Sydney, Australia
KZA Price at posting:
25.0¢ Sentiment: Buy Disclosure: Held
